🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ibrutinib-Venetoclax MRD-directed therapy vs FCR in 1L #CLL live now in NEJM Congrats to the UK CLL Study Group #ASH23 nejm.org/doi/full/10.10…

Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today nature. #lymsm 1/15 nature.com/articles/s4158… PDF link at bottom of this thread

[LYSA Days] « Follicular Lymphoma Biology and Can we Bridge the Translational Gap? » captivating presentation by Jessica Okosun Thank you Jessica! Introduced by clementine sarkozy #LYSATours24 #lymphoma

MERCI à l’incroyable team Tourangelle pour cet accueil au sommet ! Gyan Emmanuel 💪 Cc Lysa Lymphoma #LYSATours24 #LYSAvibes🏄‍♂️

LYSA is pleased to announce the creation of a new scientific committee dedicated to CLL and WM! LYSA welcomes all the French CLL/WM investigators who decided to transition from FILO to LYSA for their next studies and unifying French projects related to lymphoid malignancies.

So pleased to have attended and contributed to the #GCLLSG workshop in Cologne. Such an impressive line-up of speakers ! Thanks to #GCLLSG program committee team for the invitation. @hallekmichael

Interested to see EPCORE-CLL1 update: epcoritamab for Richter's transformation, now n=35 - ORR 50%, CR 35% - higher in treatment-naive subgroup - promising signal for a difficult-to-treat disease - combinations likely the way forward here #lymSM #EHA24 library.ehaweb.org/eha/2024/eha20…

🥳new pre-print alert! VEXAS syndrome deciphered - From single-cell genotype-to-phenotype mapping aaaall the way to mechanism and therapeutic vulnerability discovery! biorxiv.org/content/10.110…

Happy to share the results of our first #richter trial now published Nature Communications rdcu.be/dQued

Moments after you agree to write a review

HSCT for PTCL ? ascopubs.org/doi/abs/10.120… Congrats to Olivier Tournilhac ! Lysa Lymphoma @CHUClermontFd

Bispecific T-cell engagers for patients with #RichterTransformation ? Check our last paper ! Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial Nature Communications @CHUClermontFd nature.com/articles/s4146…

So grateful to have the CLL legend Estella Matutes at our FILO meeting (photo published online with permission) ! 5/5 !

🚨📣The Blood Art Contest winner has been selected! 🎉Congratulations to Alan G. Ramsay and co-authors! @ramsaylab @kingscollegelon ow.ly/f1UJ50UZig7 #bloodjournals

BIG NEWS!

Happy to share the French experience of CAR-T cells therapy for patients with #RichterTransformation ! Check our last paper. onlinelibrary.wiley.com/doi/10.1111/bj… Lysa Lymphoma @CHUClermontFd